1. Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat. Commun. 8, 1784 (2017).

2. Shreiner, A. B., Kao, J. Y. & Young, V. B. The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 31, 69–75 (2015).

3. Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).

4. Markle, J. G. et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339, 1084–1088 (2013).

5. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).

6. Zierer, J. et al. The fecal metabolome as a functional readout of the gut microbiome. Nat. Genet. 50, 790–795 (2018).

7. Wikoff, W. R. et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA 106, 3698–3703 (2009).

8. Pallister, T. et al. Hippurate as a metabolomic marker of gut microbiome diversity: modulation by diet and relationship to metabolic syndrome. Sci. Rep. 7, 13670 (2017).

9. Parker, B. L. et al. An integrative systems genetic analysis of mammalian lipid metabolism. Nature 567, 187–193 (2019).

10. Pascal, V. et al. A microbial signature for Crohn’s disease. Gut 66, 813–822 (2017).

11. Chang, J. Y. et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J. Infect. Dis. 197, 435–438 (2008).

12. Schnorr, S. L. et al. Gut microbiome of the Hadza hunter–gatherers. Nat. Commun. 5, 3654 (2014).

13. Clemente, J. C. et al. The microbiome of uncontacted Amerindians. Sci. Adv. 1, e1500183 (2015).

14. Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).

15. Sze, M. A. & Schloss, P. D. Looking for a signal in the noise: revisiting obesity and the microbiome. MBio 7, e01018-16 (2016).

16. Guh, D. P. et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9, 88 (2009).

17. Caleyachetty, R. et al. Metabolically healthy obese and incident cardiovascular disease vents among 3.5 million men and women. J. Am. Coll. Cardiol. 70, 1429–1437 (2017).

18. Kasselman, L. J., Vernice, N. A., DeLeon, J. & Reiss, A. B. The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity. Atherosclerosis 271, 203–213 (2018).

19. Price, N. D. et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat. Biotechno.l 35, 747–756 (2017).

20. Tibshirani, R. Regresion shrinkage and selection via the lasso. J. R. Stat. Soc. Series B Stat. Methodol. 73, 9 (1996).

21. Kowalska, K., Socha, E. & Milnerowicz, H. Review: the role of paraoxonase in cardiovascular diseases. Ann. Clin. Lab. Sci. 45, 226–233 (2015).

22. Myers, M. G., Leibel, R. L., Seeley, R. J. & Schwartz, M. W. Obesity and leptin resistance: distinguishing cause from effect. Trends Endocrinol. Metab. 21, 643–651 (2010).

23. Zaura, E. et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio 6, e01693-15 (2015).

24. Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108, 4554–4561 (2011).

25. Antunes, L. C. et al. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob. Agents Chemother. 55, 1494–1503 (2011).

26. Zarrinpar, A. et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism. Nat. Commun. 9, 2872 (2018).

27. Han, T. S. & Lean, M. E. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc. Dis. 5, 2048004016633371 (2016).

28. Cirulli, E. T. et al. Profound perturbation of the metabolome in obesity is associated with health risk. Cell Metab. 29, 488–500 (2018).

29. Kivimäki, M. et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120,813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health 2, e277–e285 (2017).

30. Ganz, M. L. et al. The association of body mass index with the risk of type 2 diabetes: a case-control study nested in an electronic health records system in the United States. Diabetol. Metab. Syndr. 6, 50 (2014).

31. Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541–546 (2013).

32. Larsen, O. F. A. & Claassen, E. The mechanistic link between health and gut microbiota diversity. Sci. Rep. 8, 2183 (2018).

33. Segata, N. Gut microbiome: westernization and the disappearance of intestinal diversity. Curr. Biol. 25, R611–R613 (2015).

34. van Duynhoven, J. et al. Metabolic fate of polyphenols in the human superorganism. Proc. Natl Acad. Sci. USA 108, 4531–4538 (2011).

35. Rechner, A. R. et al. Colonic metabolism of dietary polyphenols: influence of structure on microbial fermentation products. Free Radic. Biol. Med. 36, 212–225 (2004).

36. Parkar, S. G., Trower, T. M. & Stevenson, D. E. Fecal microbial metabolism of polyphenols and its effects on human gut microbiota. Anaerobe 23, 12–19 (2013).

37. Zamora-Ros, R. et al. Differences in dietary intakes, food sources and determinants of total flavonoids between Mediterranean and non-Mediterranean countries participating in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br. J. Nutr. 109, 1498–1507 (2013).

38. Koh, A. et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. Cell 175, 947–961 (2018).

39. Gryp, T., Vanholder, R., Vaneechoutte, M. & Glorieux, G. p-Cresyl sulfate. Toxins 9, E52 (2017).

40. Manor, O. et al. A multi-omic association study of trimethylamine N-oxide. Cell Rep. 24, 935–946 (2018).

41. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).

42. Yao, C. K., Muir, J. G. & Gibson, P. R. Review article: insights into colonic protein fermentation, its modulation and potential health implications. Aliment. Pharmacol. Ther. 43, 181–196 (2016).

43. Fui, M. N., Dupuis, P. & Grossmann, M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J. Androl. 16, 223–231 (2014).

44. Vanholder, R., Schepers, E., Pletinck, A., Nagler, E. V. & Glorieux, G. The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J. Am. Soc. Nephrol. 25, 1897–1907 (2014).

45. Bogiatzi, C. et al. Metabolic products of the intestinal microbiome and extremes of atherosclerosis. Atherosclerosis 273, 91–97 (2018).

46. Salgado, R., López-Doval, S., Pereiro, N. & Lafuente, A. Perfluorooctane sulfonate (PFOS) exposure could modify the dopaminergic system in several limbic brain regions. Toxicol. Lett. 240, 226–235 (2016).

47. Onishchenko, N. et al. Prenatal exposure to PFOS or PFOA alters motor function in mice in a sex-related manner. Neurotox. Res. 19, 452–461 (2011).

48. Lai, K. P. et al. Dietary exposure to the environmental chemical, PFOS on the diversity of gut microbiota, associated with the development of metabolic syndrome. Front. Microbiol. 9, 2552 (2018).

49. Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).

50. Hibberd, M. C. et al. The effects of micronutrient deficiencies on bacterial species from the human gut microbiota. Sci. Transl. Med. 9, eaal4069 (2017).

51. Watson, H. et al. A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota. Gut 67, 1974–1983 (2018).

52. Li, M. et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc. Natl Acad. Sci. USA 105, 2117–2122 (2008).

53. Poesen, R. et al. Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J. Am. Soc. Nephrol. 27, 3479–3487 (2016).

54. Moss, C. W., Lambert, M. A. & Goldsmith, D. J. Production of hydrocinnamic acid by clostridia. Appl. Microbiol. 19, 375–378 (1970).

55. Nealon, N. J., Worcester, C. R. & Ryan, E. P. Lactobacillus paracasei metabolism of rice bran reveals metabolome associated with Salmonella typhimurium growth reduction. J. Appl. Microbiol. 122, 1639–1656 (2017).

56. Beuers, U., Fischer, S., Spengler, U. & Paumgartner, G. Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. J. Hepatol. 13, 97–103 (1991).

57. Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).

58. DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Environ. Microbiol. 72, 5069–5072 (2006).

59. Weiss, S. et al. Normalization and microbial differential abundance strategies depend upon data characteristics. Microbiome 5, 27 (2017).

60. Hughes, J. B., Hellmann, J. J., Ricketts, T. H. & Bohannan, B. J. Counting the uncountable: statistical approaches to estimating microbial diversity. Appl. Environ. Microbiol. 67, 4399–4406 (2001).

61. Faith, D. P. & Baker, A. M. Phylogenetic diversity (PD) and biodiversity conservation: some bioinformatics challenges. Evol. Bioinform. Online 2, 121–128 (2007).

62. Anderson, M. J. A new method for non-parametric multivariate analysis of variance. Austral Ecol. 26, 32–46 (2001).

63. Anderson, M. J. Distance-based tests for homogeneity of multivariate dispersions. Biometrics 62, 245–253 (2006).